stockrowAdaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
Follow ADPT
Alert me
Adaptive Biotechnologies Corporation (ADPT) Revenue
Adaptive Biotechnologies Corporation's revenue for fiscal 2025 was $277.0M, up 54.8% from $179.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $298.0M. Over the past ten years it has ranged from $38.4M (fiscal 2017) to $277.0M (fiscal 2025) — the current reading is the highest in ten years. Adaptive Biotechnologies Corporation ranks 29th of 47 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $277.0M | 54.77% |
| FY2024 | $179.0M | 5.10% |
| FY2023 | $170.3M | (8.11%) |
| FY2022 | $185.3M | 20.06% |
| FY2021 | $154.3M | 56.88% |
| FY2020 | $98.4M | 15.65% |
| FY2019 | $85.1M | 52.83% |
| FY2018 | $55.7M | 44.77% |
| FY2017 | $38.4M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $83.9M | 17.26% |
| Jun 2026 | $71.6M | 0.96% |
| Mar 2026 | $70.9M | (1.13%) |
| Dec 2025 | $71.7M | (23.72%) |
| 29 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| RDNT RadNet, Inc. compare | $2.3B |
| SHC Sotera Health Company compare | $1.2B |
| NEO NeoGenomics, Inc. compare | $787.8M |
| VCYT Veracyte, Inc. compare | $581.8M |
| CDNA CareDx, Inc. compare | $497.4M |
| WGS GeneDx Holdings Corp. compare | $454.4M |
| BLLN BillionToOne, Inc. compare | $436.9M |
| ADPT Adaptive Biotechnologies Corporation | $298.0M |
| GRAL GRAIL, Inc. compare | $166.6M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ADPT
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement